Crossject Société Anonyme, a company incorporated in 2001 and headquartered in Dijon, France, operates within the Health Care Equipment & Supplies sector. The company specializes in the development of needle-free injection systems, with its flagship product being ZENEO, a needle-free, pre-filled, single-use auto-injector. ZENEO is designed to deliver a range of medications, including Midazolam for epileptic seizures, Naloxone for opioid overdoses, Terbutaline for severe asthma crises, Epinephrine for anaphylactic shock, Sumatriptan for migraines and cluster headaches, Hydrocortisone for acute adrenal crises, and Methotrexate for rheumatoid arthritis treatment.
In addition to ZENEO, Crossject is advancing its product pipeline with ZEPIZURE, an emergency treatment specifically aimed at managing epileptic seizures. This innovation underscores the company’s commitment to addressing critical healthcare needs through advanced delivery technologies.
As of January 20, 2026, Crossject has not reported any new developments. The most recent significant update occurred on November 14, 2025, when the company announced securing €5 million in financing from Vatel Capital, as reported by wallstreet-online.de. This financial boost is likely to support ongoing research and development efforts.
In terms of financial performance, Crossject’s shares are traded on the NYSE Euronext Paris, with the currency of transaction being the Euro (EUR). As of January 19, 2026, the closing price of Crossject’s shares was €2.035. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of €2.695 on November 12, 2025, and a 52-week low of €0.7199 on April 10, 2025. This indicates a trading range of approximately €1.98. The current share price of €2.06 is positioned roughly 24% below the annual high and 78% above the annual low, placing it in a mid-range position within its one-year volatility envelope.
Crossject’s market capitalization stands at €107,464,512, reflecting its valuation in the healthcare sector. The company’s focus on innovative needle-free injection technologies positions it as a key player in the development of advanced medical delivery systems, addressing a variety of urgent healthcare needs.
